21 Partners-backed Synerlab acquires Alcalá Farma

Synerlab acquired the company to gain access to the Spanish contract development and manufacturing organisation market and Alcalá's development capabilities, among other reasons.

21 Partners stated that the acquisition of Alcalá was the first step in a wider consolidation strategy for Synerlab.

Ardian sold Synerlab to 21 Partners in a management buyout in 2013, but reinvested in the company as part of the transaction.

Ardian (then Axa Private Equity) acquired Synerlab in April 2007 from Adlinger & Company. The deal was valued at €100m, according to unquote" data, and saw Ardian take a majority stake in the business, while Natixis underwrote a senior debt package for the deal.

Companies
Founded in 1995, Alcalá is a developer and manufacturer of pharmaceutical and dietary products. It also offers medicinal implants and nutritional and cosmetic supplements in Europe. The firm is based in Alcalá de Henares, Spain.

Founded in 2001, Synerlab is headquartered in Erstein and employs 600 staff. The group comprises five entities: production sites Laboratoires BTT, Sophartex, Pharmaster and Lyofal, and research and development centre Synerlab Développement.

The group manufactures dry and liquid products for the pharmaceutical industry, such as syrups, capsules, tablets and sachets. The company also creates packaging for medicinal products.

People
Pierre Banzet is the CEO of Synerlab. Gérard Pluvinet is the founding managing partner and Jacques Rossignol is a managing partner at 21 Partners. Alexis Lavaillote is a managing director at Ardian Expansion.

Advisers
Equity – CMS, Francis Lefbvre (Legal); PwC (Financial due diligence); Roland Berger Consultants (Commercial due diligence).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Southern Europe
• Healthcare
• Expansion
• France
• Spain
• Build-up